IS'ECHO : Impact of Bursitis on the Efficacy of Subacromial Steroid Injection in Rotator Cuff Tendinopathy

Completed

• Conditions: Rotator Cuff Tendinopathy

• Registration Number: NCT03454321
• Lead Sponsor: Nantes University Hospital

Brief Summary

Shoulder pain is a common reason for medical consultation affecting 6.7 % of the adults from 50 to 70 years old and until 21 % of the adults over 70. Among these painful shoulders, rotator cuff tendinopathy represents 44 to 65% of these consultations. To treat this condition, patients usually receive analgesics and physical therapy. When these treatments are not effective, a corticosteroid sub-acromial injection is proposed. However, according to the literature, there is only about 50% of good response to this subacromial injection in rotator cuff tendinopathy. It has been suggested that the injection could be more effective in the presence of an inflammation over the tendons called bursitis. However, no studies have clearly established this. The objective of the study is to determine if the presence of a bursitis could be a factor of good response to corticosteroid injection. The results could allow us to determine which patients have the best profile to respond to subacromial injection. The investigators hope that these data would improve the treatment of this frequent disease.

Detailed Description

Patients referred to receive a subacromial ultrasound-guided injection for shoulder pain related to a rotator cuff tendinopathy will be enrolled in the study. After validation of the inclusion criteria, the participants will receive oral information about the protocol. Then, they will be examined and will undergo X-rays and an ultrasound of their shoulder. Pain shoulder and shoulder disability will be assessed before the injection with a visual analogic pain scale and the Oxford Shoulder Score questionnaire, respectively.

The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.

After the procedure, the participants will all receive a standardized physiotherapy.

For primary outcome, the therapeutic response will be assessed 3 months after the procedure. Patients will be considered as having a good response if their level of pain decreases by over 30%.

The number of participants having a good clinical response will be compared between the patients presenting a bursitis and those without bursitis. The comparison will be made using a Chi-2 test.

Others parameters will be studied: reduction in pain 6 weeks after the injection, reduction in shoulder disability 6 weeks and 3 months after the injection. Other ultrasound lesions will be collected so as X-ray features to search other factors associated with the presence or absence of a good therapeutic response (details in secondary outcomes).

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-02-13
• Study First Submitted QC: 2018-03-02
• Study First Posted: 2018-03-05
• Study Start: 2018-03-15
• Primary Completion: 2021-03-31
• Status Verified: 2021-09
• Study Completion: 2021-09-01
• Last Update Submitted: 2021-09-10
• Last Update Posted: 2021-09-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Major patients with manifestations of rotator cuff tendinopathy referred to our rheumatology department to receive an ultrasound-guided subacromial injection.

Read More

Exclusion Criteria

• Patients refusing to participate
• Allergic to local anesthetics
• Shoulder involvement of an inflammatory rheumatic disease
• History of shoulder surgery
• Shoulder instability
• Glenohumeral osteoarthritis
• Frozen shoulder
• Extended rotator cuff tear
• Tendinous calcification > 0.5 cm
• Pregnant women
• Minors
• Majors under guardianship
• Patient inappropriate for entry into this study according to the judgment of the investigator

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in shoulder pain 3 months after the subacromial corticosteroid injection	3 months	The primary outcome is the presence of a therapeutic response 3 months after the intervention. The level of pain will be assessed by a visual analogic pain scale of 0 (absence of pain) to 10 centimeters (maximal pain).; Participants will be considered as good responders if their level of pain decreases more than 30 percent.; Safety issue: No

Secondary Outcome Measures

Name	Time	Method
Reduction in shoulder pain 6 weeks after the subacromial steroid injection.	6 weeks after the intervention	Presence of a therapeutic response 6 weeks after the intervention considering the reduction in pain between day 0 and Week 6 and assessed with the same scale as the primary outcome. Participants will be considered as good responders if their level of pain decreases more than 30 percent.
Presence of radiographic abnormalities associated with a good response.	data from Day 0, Week 6 and Month 3	X-ray data = Acromion Morphology according to Park's classification, Critical Shoulder Angle, acromioclavicular osteoarthritis
Presence of other ultrasound lesions associated with a good response to steroid injection	data from Day 0, Week 6 and Month 3	The ultrasound lesions collected just before the injection will be : * Bursitis: the bursitis is defined by a thickening of more than 2 mm of the subacromial bursae.; * Tendinous lesions (supra-spinatus, infra-spinatus or sub-scapularis): tendon thickening, hypoechoic density, presence of microcalcification, partial or complete tear; * Effusion of long head of biceps tendon sheath; * Acromio-clavicular joint lesions = synovitis, presence of Doppler flow, osteophytes
Steroid injection safety	data from Day 0, Week 6 and Month 3	Adverse events will be collected after the procedure and during follow-up.
Reduction in OSS score (Oxford Shoulder Score) 6 weeks and 3 months after the injection	data from Day 0, Week 6 and Month 3	The OSS is a 12-item shoulder-specific questionnaire that was developed, with patients, for the assessment of shoulder pain and function. Items refer to the past 4 weeks and each offers five ordinal response options. These were scored from 1 to 5 (5 = most severe) and then conbined to produce a single score with a range from 12 (least difficulties) to 60 (most difficulties).

Trial Locations

Locations (1)

Chu de Nantes; 🇫🇷 Nantes, France